
|Videos|December 15, 2020
Overview of the PIONEER Clinical Trial Program for Oral Semaglutide
Results from the PIONEER clinical trials program indicate that the first oral glucagon-like peptide-1 receptor agonist (GLP-1RA), oral semaglutide, provides effective glycemic control across a range of different patient populations.
Click PLAY to watch the video abstract.
Click
Click
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Latest CME
Trending on AJMC
1
Elinzanetant Shows Consistent Efficacy, Safety, and Sleep Benefits Across Studies
2
Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD
3
Elinzanetant Shows Strong 52-Week Safety for Vasomotor Symptoms: James Simon, MD
4
GLP-1 Receptor Agonists May Improve Rheumatoid Arthritis Symptoms
5












































